We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics

By LabMedica International staff writers
Posted on 26 Jan 2024

Seegene, Inc. More...

(Seoul, Korea) and Microsoft (Redmond, WA, USA) have entered into a strategic collaboration that opens up a new chapter in the field of molecular diagnostics to realize 'a world free from all diseases and future pandemics'.

Seegene has selected Microsoft as a technology partner for its SG OneSystem business to realize 'a world free from all diseases.' By collaborating with Microsoft to drive the growth of its SG OneSystem business, Seegene has adopted an unprecedented strategy of sharing its unique syndromic quantitative PCR technologies with the world’s leading companies to encourage cross-industry innovation in molecular diagnostics. The expansion of participating companies, with whom Seegene aims to form a global consortium, will empower countries across the world with optimal solutions, enabling them to effectively address future pandemics and collectively move closer to 'a world free from all diseases.'

To achieve this goal, Seegene will work with Microsoft's global healthcare team to help further SG OneSystem's growth by advocating the collective vision, bridging potential partners, and jointly participating in SG OneSystem's annual symposium. Other key events connecting current and prospective SG OneSystem partners, such as a declaration ceremony for scientific communities and other partners participating in the SG OneSystem business will be held within the first half of this year to commemorate the shared vision. Seegene's Digitalized Development System (SGDDS) will integrate Microsoft Azure services, including Azure OpenAI Service, which will be used by Seegene to handle the landscape of data interaction and analysis for researchers dealing with extensive data generated by the SGDDS. The implementation of the highly secure and compliant Azure Trusted Research Environment (TRE) will push the boundaries of PCR research, helping ensure both privacy and regulatory adherence.

Seegene will implement Microsoft Fabric, a single AI-powered analytics platform that will unify Seegene's data and reshape how everyone accesses, manages, and acts on that data with capabilities that span data integration, data engineering, data science, data monitoring, real-time analytics, and business intelligence. The integration of AI-driven assistance through Copilot for Microsoft 365 is expected to accelerate productivity, foster innovation and enhance creativity. Furthermore, Seegene will collaborate with Microsoft on collective healthcare innovation research, including next-generation management and analytics for PCR data, and explore future ventures within the healthcare sector. Seegene aims to improve the healthcare ecosystem with Microsoft by delivering accurate early disease diagnoses that provide the foundation for effective treatment and prevention.

"The strategic collaboration with Microsoft will allow us to have a more structured SG OneSystemTM business model," said Dr. Jong-Yoon Chun, CEO and founder of Seegene. "Through our joint efforts, we expect synergetic effects to pave the way for a world free from all diseases."

"We support Seegene's vision of realizing 'a world free from all diseases,'" added Elena Bonfiglioli, General Manager, Global Health and Life Sciences at Microsoft. "In addition to working with Seegene on its digital transformation, we will collaborate to discover global partners and to further enhance the healthcare ecosystem."

Related Links:
Seegene, Inc.
Microsoft


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.